Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency

Vaccine

Volumn 32, Issue 19, 2014, Pages 2188-2197

  Khurana, Surender ^a   King, Lisa R ^a   Manischewitz, Jody ^a   Coyle, Elizabeth M ^a   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Hemagglutinin; Influenza; Potency; SPR; SRID; Vaccine

Indexed keywords

ADJUVANT; GALACTOSE; GLYCAN; HEMAGGLUTININ; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; SIALIC ACID;

2009 H1N1 INFLUENZA; ANTIBODY INDEPENDENT RECEPTOR BINDING SURFACE PLASMON RESONANCE; ARTICLE; ASSAY; DRUG POTENCY; GEL FILTRATION CHROMATOGRAPHY; HEMAGGLUTINATION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N7; INTERMETHOD COMPARISON; MEASUREMENT; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RECEPTOR BINDING; REPRODUCIBILITY; SURFACE PLASMON RESONANCE; VIRUS STRAIN;

HEMAGGLUTININ; INFLUENZA; POTENCY; SPR; SRID; VACCINE;

HEMAGGLUTINATION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNODIFFUSION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; N-ACETYLNEURAMINIC ACID; POLYSACCHARIDES; REPRODUCIBILITY OF RESULTS; SURFACE PLASMON RESONANCE; VACCINE POTENCY;

EID: 84897110244     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.049     Document Type: Article

References (40)

1. Williams M.S., Mayner R.E., Daniel N.J., Phelan M.A., Rastogi S.C., Bozeman F.M., et al. New developments in the measurement of the hemagglutinin content of influenza virus vaccines by single-radial-immunodiffusion. J Biol Stand 1980, 8(4):289-296.
2. Wood J.M., Mumford J., Schild G.C., Webster R.G., Nicholson K.G. Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals. Dev Biol Stand 1986, 64:169-177.
3. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21(May (16)):1776-1779.
4. Compans R.W., Klenk H.D., Caliguiri L.A., Choppin P.W. Influenza virus proteins. I. Analysis of polypeptides of the virion and identification of spike glycoproteins. Virology 1970, 42(December (4)):880-889.
5. Brand C.M., Skehel J.J. Crystalline antigen from the influenza virus envelope. Nat New Biol 1972, 238(August (83)):145-147.
6. Schmeisser F., Vodeiko G.M., Lugovtsev V.Y., Stout R.R., Weir J.P. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 2010, 28(March (12)):2442-2449.
7. Khurana S., Larkin C., Verma S., Joshi M.B., Fontana J., Steven A.C., et al. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 2011, 29(August (34)):5657-5665.
8. Hardy S., Eichelberger M., Griffiths E., Weir J.P., Wood D., Alfonso C. Confronting the next pandemic - workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010. Influenza Other Respir Viruses 2011, 5(6 (November)):438-442.
9. Luykx D.M., Casteleijn M.G., Jiskoot W., Westdijk J., Jongen P.M. Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur J Pharm Sci 2004, 23(September (1)):65-75.
10. Farnsworth A., Cyr T.D., Li C., Wang J., Li X. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 2011, 29(February (8)):1529-1533.
11. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2011, 375(January (9708)):41-48.
12. Williams T.L., Luna L., Guo Z., Cox N.J., Pirkle J.L., Donis R.O., et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008, 26(May (20)):2510-2520.
13. Williams T.L., Pirkle J.L., Barr J.R. Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry. Vaccine 2011, 30(March (14)):2475-2482.
14. Getie-Kebtie M., Chen D., Eichelberger M., Alterman M. Proteomics-based characterization of hemagglutinins in different strains of influenza virus. Proteomics Clin Appl 2009, 3(August (8)):979-988.
15. Creskey M.C., Smith D.G., Cyr T.D. Strain identification of commercial influenza vaccines by mass spectrometry. Anal Biochem 2010, 406(November (2)):193-203.
16. Wilson I.A., Skehel J.J., Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981, 289(January (5796)):366-373.
17. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol 2010, 85(February (3)):1246-1256.
18. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., et al. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE 2010, 5(7):e11548.
19. Verma S., Dimitrova M., Munjal A., Fontana J., Crevar C.J., Carter D.M., et al. Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies. J Virol 2012, 86(November (22)):12283-12293.
20. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56(March (1)):152-179.
21. Connor R.J., Kawaoka Y., Webster R.G., Paulson J.C. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 1994, 205(November (1)):17-23.
22. Wang Y.F., Chang C.F., Chi C.Y., Wang H.C., Wang J.R., Su I.J. Characterization of glycan binding specificities of influenza B viruses with correlation with hemagglutinin genotypes and clinical features. J Med Virol 2012, 84(April (4)):679-685.
23. Hashem A.M., Gravel C., Farnsworth A., Zou W., Lemieux M., Xu K., et al. A novel synthetic receptor-based immunoassay for influenza vaccine quantification. PLoS ONE 2013, 8(2):e55428.
24. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines. Dev Biol Stand 1977, 39(June):193-200.
25. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977, 5(3):237-247.
26. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(March (13)):1343-1351.
27. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008 Mar 1, 197(5):667-675.
28. Khurana S., Chearwae W., Castellino F., Manischewitz J., King L.R., Honorkiewicz A., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2(15). p. 15ra5-ra5.
29. Khurana S., Verma N., Yewdell J.W., Hilbert A.K., Castellino F., Lattanzi M., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011, 3(June (85)):85ra48.
30. Langley J.M., Frenette L., Ferguson L., Riff D., Sheldon E., Risi G., et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010, 201(June (11)):1644-1653.
31. White J.M., Wilson I.A. Anti-peptide antibodies detect steps in a protein conformational change: low-pH activation of the influenza virus hemagglutinin. J Cell Biol 1987, 105(6 Pt 2 (December)):2887-2896.
32. Chen J., Lee K.H., Steinhauer D.A., Stevens D.J., Skehel J.J., Wiley D.C. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 1998, 95(3 (October)):409-417.
33. Nilsson C.E., Abbas S., Bennemo M., Larsson A., Hamalainen M.D., Frostell-Karlsson A. A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 2010, 28(January (3)):759-766.
34. Zhang Q., Shi J., Deng G., Guo J., Zeng X., He X., et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013, 341(July (6144)):410-414.
35. Zhu H., Wang D., Kelvin D.J., Li L., Zheng Z., Yoon S.W., et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 2013, 341(July (6142)):183-186.
36. Xiong X., Martin S.R., Haire L.F., Wharton S.A., Daniels R.S., Bennett M.S., et al. Receptor binding by an H7N9 influenza virus from humans. Nature 2013, 499(July (7459)):496-499.
37. Xiong X., Coombs P.J., Martin S.R., Liu J., Xiao H., McCauley J.W., et al. Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature 2013, 497(May (7449)):392-396.
38. Steinhauer D.A. Influenza: pathways to human adaptation. Nature 2013, 499(July (7459)):412-413.
39. Christensen L.L. Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Anal Biochem 1997, 249(July (2)):153-164.
40. Richalet-Secordel P.M., Rauffer-Bruyere N., Christensen L.L., Ofenloch-Haehnle B., Seidel C., Van Regenmortel M.H. Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. Anal Biochem 1997, 249(July (2)):165-173.